Investing News

Pfizer Earnings Weighed Down Again by Dwindling COVID Sales

The company reiterated its recent reduction in full-year sales guidance by $9 billion as it doubled down on efforts to trim costs.

Articles You May Like

Trade Broken Trendlines Without Going Broke
What Are the Three Stages of the IPO Life Cycle?
The Invisible Hand of AI: 3 Robotics Stocks Shaping the Future
3 Must-Sell Stocks: Protect Your Profits from the Looming 2024 Hurricane Season Chaos
The 3 Most Undervalued Russell 2000 Stocks to Buy in May 2024